Locations:
Min Investment:
Max Investment:
Target Investment:
Ph.D.
(2000 - 2003)
B.Sc (Hons)
(1995 - 2000)
2021
2022
First-in-class small inhibitors for treatment of a range of neurodegenerative diseases by safely counteracting glutamate excitotoxicity.
2022
2022
2022
Fibrocor utilizes its proprietary drug discovery engine to develop new medicines for individuals with fibrotic diseases.
2021
2021
2022
2022
T-reg targeted therapies for long-lasting autoimmune disease control
2017 - 2021
2021 - 2021
Strategic corporate venture capital arm of Merck, with €300m of investable capital. I invest in innovation, being jointly responsible for all biotechnology investments (biotherapeutics and life sciences tools and consumables). I act as the Life Sciences Interface with Merck.
2020 - 2021
2017 - 2020
2021 - 2021
2021 - 2021
Riffyn’s pioneering cloud system, Riffyn Nexus, is a process data system that places R&D process flows at the center of heterogeneous and fragmented R&D environments, delivering 2X faster development cycles and 4X productivity gains to the world’s scientific R&D organizations. Its process-centric experiment design, data capture, and data analytics overcome the limitations of traditional scientific data systems — delivering results that are always ready for machine learning.
2020 - 2021
2020 - 2021
DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science. The company is pioneering an alternative to traditional DNA synthesis called enzymatic DNA synthesis, or EDS, making this technology accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX™ System.
2019 - 2021
2019 - 2021
Single cell genomics-based approaches to identify novel immuno-oncology targets